158 related articles for article (PubMed ID: 22097958)
1. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Yang Y; Shen Y; Liu H; Yao X
J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
[TBL] [Abstract][Full Text] [Related]
2. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
3. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
4. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Gao C; Grøtli M; Eriksson LA
J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Kano MR; Komuta Y; Iwata C; Oka M; Shirai YT; Morishita Y; Ouchi Y; Kataoka K; Miyazono K
Cancer Sci; 2009 Jan; 100(1):173-80. PubMed ID: 19037999
[TBL] [Abstract][Full Text] [Related]
6. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
7. Affinity purification of protein kinases that adopt a specific inactive conformation.
Ranjitkar P; Maly DJ
Methods Mol Biol; 2012; 928():143-51. PubMed ID: 22956139
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Heinrich MC; Marino-Enriquez A; Presnell A; Donsky RS; Griffith DJ; McKinley A; Patterson J; Taguchi T; Liang CW; Fletcher JA
Mol Cancer Ther; 2012 Aug; 11(8):1770-80. PubMed ID: 22665524
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
10. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
11. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
[TBL] [Abstract][Full Text] [Related]
12. The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
Tecle H; Feru F; Liu H; Kuhn C; Rennie G; Morris M; Shao J; Cheng AC; Gikunju D; Miret J; Coli R; Xi SH; Clugston SL; Low S; Kazmirski S; Ding YH; Cao Q; Johnson TL; Deshmukh GD; DiNitto JP; Wu JC; English JM
Chem Biol Drug Des; 2009 Dec; 74(6):547-59. PubMed ID: 19843080
[TBL] [Abstract][Full Text] [Related]
13. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.
Angell RM; Angell TD; Bamborough P; Bamford MJ; Chung CW; Cockerill SG; Flack SS; Jones KL; Laine DI; Longstaff T; Ludbrook S; Pearson R; Smith KJ; Smee PA; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Aug; 18(15):4433-7. PubMed ID: 18602262
[TBL] [Abstract][Full Text] [Related]
14. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
[TBL] [Abstract][Full Text] [Related]
16. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Abe K; Toba M; Alzoubi A; Koubsky K; Ito M; Ota H; Gairhe S; Gerthoffer WT; Fagan KA; McMurtry IF; Oka M
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):804-8. PubMed ID: 21378262
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
19. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
[TBL] [Abstract][Full Text] [Related]
20. Insights into MAPK p38alpha DFG flip mechanism by accelerated molecular dynamics.
Filomia F; De Rienzo F; Menziani MC
Bioorg Med Chem; 2010 Sep; 18(18):6805-12. PubMed ID: 20724167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
